Spruce Biosciences Completes Target Enrollment Of CAHmelia-203 Study In Adult Classic Congenital Adrenal Hyperplasia
Portfolio Pulse from Benzinga Newsdesk
Spruce Biosciences has completed target enrollment for its CAHmelia-203 study in adult classic congenital adrenal hyperplasia. The final enrollment is expected to exceed the target due to substantial patient interest. Topline results for the study are anticipated in the first quarter of 2024. The company also anticipates the completion of enrollment for CAHmelia-204 in early first quarter of 2024.
October 18, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spruce Biosciences has completed target enrollment for its CAHmelia-203 study, with results expected in Q1 2024. The company also expects to complete enrollment for CAHmelia-204 in early Q1 2024.
The completion of target enrollment for the CAHmelia-203 study indicates progress in Spruce Biosciences' research and development efforts. This could potentially lead to positive outcomes for the company, including the approval and commercialization of new treatments, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100